![ECOG-ACRIN logo[19516]275×75](https://blog.ecog-acrin.org/wp-content/uploads/2021/03/ECOG-ACRIN-logo19516275x75.png)
June 25, 2025
This clinical trial is evaluating a new drug combination for patients with B-cell lymphoma that has relapsed after remission or no longer responds to standard treatment
June 11, 2025
Grant updates; engineering and cancer research; Spring Group Meeting and ASCO highlights
June 11, 2025
Dr. Grivas is honored as an international key opinion thought leader who has made outstanding contributions to genitourinary cancer research, clinical practice, leadership, teaching and mentorship, and community outreach
June 11, 2025
The group is recognizing Dr. Schiller for her sustained commitment to mentoring early- and mid-career investigators in cancer medicine
June 11, 2025
The changes broaden eligibility and clarify treatment planning details in this phase 2 trial testing daratumumab-hyaluronidase to eliminate minimal residual disease after initial chemotherapy
June 11, 2025
Researchers with the ECOG-ACRIN Cancer Research Group presented a number of research findings at the 2025 ASCO Annual Meeting
June 11, 2025
Summaries and links to timely information about research results presented at medical meetings, recognition of research leaders, and more